Navigation Links
Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Date:9/4/2007

ients have had a maximum Grade 1 QTc interval prolongation, and 7 patients a maximum Grade 2; the increases were clinically asymptomatic and not associated with AEs or dose reduction or delay. One patient who experienced an event of asymptomatic Grade 3 QTc interval prolongation had ineligible baseline QTc values (Grade 2) and was withdrawn from the study. A total of 16 serious AEs were reported in 8 patients. 5 events in 4 patients were considered possibly or probably related to study drug: Grade 3 GI hemorrhage and duodenal ulcer in 1 patient, and Grade 3 pneumonia, Grade 4 pulmonary embolism, and Grade 2 haemoptysis.

About XL647

XL647 is a potent inhibitor of receptor tyrosine kinases (RTKs) that are implicated in driving tumor proliferation and vascularization (blood vessel formation). XL647 inhibits EGFR, HER2 and VEGFR2. The compound has been optimized for high potency and oral bioavailability (using in vivo systems), demonstrates excellent activity in target-specific cellular functional assays and has shown sustained inhibition of target RTKs preclinically in vivo following a single oral dose. Two phase 2 trials in patients with NSCLC are ongoing.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at <
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... York (PRWEB) August 29, 2014 ... at $5.6 billion in 2019. It is expected ... 2013 to 2019, and was valued at $1.8 ... published by Transparency Market Research. , For more ... http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research report, titled ...
(Date:8/29/2014)... 29, 2014 Local veterinarian, Dr. Keith ... are seeking candidates to participate in an investigational study ... The ultimate goal of this study is to determine ... one or two arthritically affected joints can help reduce ... Candidates for the current investigational study must be older ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Intrinsic ... 13485:2003 certified, GAMP® 5 compliant imaging core lab, ... international Phase II clinical trial to assess a ... Throughout this trial, Intrinsic Imaging will provide comprehensive ... to, protocol and charter development, site qualification, site ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency and ... 150 ppb,” said Mark Tess, PhD, Mycotoxin Product Manager for ... owners and USDA-GIPSA inspection agencies that have a need to ... place in a matter of minutes with nothing but our ... feed and grain before accepting it, but they no longer ...
Breaking Biology Technology:Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
... Sept. 21 Mr. Paw Yew Hock, the newly appointed Interim ... Ltd.)("China Agro") announced today the reorganization of the Company in order ... biotech marketplaces. , , Mr. Paw noted that ... Company has put in place a seasoned board and management team, ...
... , WORCESTER, Mass., Sept. 21 ... Dr. Robert Lanza, its Chief Scientific Officer, will be featured ... an hour long radio program on science, technology, politics, and ... in New York City (WBAI 99.5 FM), and re-aired in ...
... , WEST CONSHOHOCKEN, Pa., Sept. 21 Cadient ... industry, today announced that two web sites it developed and designed have ... magazine,s MM&M Awards for the Best Web Site category. ... web site developed by Cadient Group for AstraZeneca and the ...
Cached Biology Technology:China Agro-Technology Holdings Reorganized 2Dr. Robert Lanza Featured on Michio Kaku's 'Explorations in Science' 2Dr. Robert Lanza Featured on Michio Kaku's 'Explorations in Science' 3Cadient Group Selected as Finalist in Medical Marketing & Media Awards 2
(Date:8/28/2014)... have identified a handful of bacterial culprits that may ... and ulcerative colitis, using patients, own intestinal immune responses ... 28 in the journal Cell . , Trillions ... plays a critical role in the development and progression ... number of bacterial species affect a person,s susceptibility to ...
(Date:8/28/2014)... MD FASEB MARC (Maximizing Access to Research Careers) ... American Society of Human Genetics from October 18 ... are meant to promote the entry of students, post ... of the basic science community and to encourage the ... Human Genetics. This year MARC conferred 16 awards ...
(Date:8/28/2014)... support of peer groups and clinicians is critical ... to recent University of Georgia research. , A ... County area determined that role models for successful ... of infants. , "Mothers who received that support ... said study co-author Alex Anderson, an associate professor ...
Breaking Biology News(10 mins):Yale study identifies possible bacterial drivers of IBD 2Breastfeeding study shows need for effective peer counseling programs 2
... (June 23, 2009) University of Minnesota Medical School researchers have ... may work to treat those infected by a parasitic flatworm. ... The Schistosomasis parasite infects about 200 million ... 70 countries, where people become infected simply by bathing, drinking, or ...
... indicates the way our brain handles how we move ... someone else,s shoesmay be related to how and why ... recently published in the online scientific journal PLoS ... http://tinyurl.com/lw6qmv . Empathy involves, in part, the ability ...
... Microbiome Project has awarded more than $42 million to expand its ... or on our bodies affect our health, the National Institutes of ... all the microorganisms that reside in or on the human body, ... as part of the NIH Common Fund,s Roadmap for Medical Research, ...
Cached Biology News:U of M study finds new insight on therapy for a devastating parasitic disease 2Ability to literally imagine oneself in another's shoes may be tied to empathy 2Ability to literally imagine oneself in another's shoes may be tied to empathy 3NIH expands Human Microbiome Project; funds sequencing centers and disease projects 2NIH expands Human Microbiome Project; funds sequencing centers and disease projects 3NIH expands Human Microbiome Project; funds sequencing centers and disease projects 4NIH expands Human Microbiome Project; funds sequencing centers and disease projects 5
...
... to MSY2/YBOX2 ( Abpromise for ... Antigen: Synthetic peptide derived from ... of human YBX2. (Note: the ... Entrez ...
... Freedom EVO384R are fast multi-channel pipetting platforms ... different sizes, with a multi-channel head and ... time saving, with true parallel processing of ... your assays with the Freedom EVOware program. ...
... Aminopropylsilane is perhaps the ... chemistry for microarray experiments. ... for Microarrays provide a ... for printing PCR products ...
Biology Products: